Media Articles Related to Mozobil (Plerixafor Subcutaneous)
First Drug Approved for Marginal Zone Lymphoma
Source: Medscape Hematology-Oncology Headlines [2017.01.19]
Ibrutinib is the first drug to be specifically approved for marginal zone lymphoma, which accounts for about 12% of all non-Hodgkin’s lymphomas.
Advances in multiple myeloma, lymphoma and other hematologic malignancies presented at ASH
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2016.12.07]
Researchers from University Hospitals Seidman Cancer Center and Case Western Reserve University School of Medicine presented significant new research findings in multiple myeloma, lymphoma and...
Combination immune therapy shows promise against Hodgkin lymphoma
Source: Clinical Trials / Drug Trials News From Medical News Today [2016.12.06]
The combination of two new drugs that harness the body's immune system is safe and effective, destroying most cancer cells in 64 percent of patients with recurrent Hodgkin lymphoma, according to...
Researchers document first reported case of an intermediate stage of lymphoma transformation
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2016.11.23]
An uncommon case of blood cancer non-Hodgkin lymphoma developing into classical Hodgkin lymphoma was recently described by American researchers in a case report published in the journal Advances in...
Immune Therapy Makes Headway Against a Lymphoma
Source: MedicineNet Non-Hodgkins Lymphomas Specialty [2016.09.09]
Title: Immune Therapy Makes Headway Against a Lymphoma
Category: Health News
Created: 9/8/2016 12:00:00 AM
Last Editorial Review: 9/9/2016 12:00:00 AM
Published Studies Related to Mozobil (Plerixafor Subcutaneous)
Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. [2009.12]
In a phase 3 multicenter, randomized, double-blinded, placebo-controlled study of 298 patients with non-Hodgkin lymphoma (NHL), granulocyte colony-stimulating factor (G-CSF) plus plerixafor increased the proportion of patients who mobilized >or=5 x 10(6) CD34(+) hematopoietic stem cells (HSCs)/kg compared with placebo plus G-CSF (P < .001).
Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. [2009.10.01]
PURPOSE: This study evaluates the safety and efficacy of plerixafor (AMD3100), a CXCR4 antagonist, in mobilizing hematopoietic stem cells for autologous stem-cell transplantation in non-Hodgkin's lymphoma (NHL) patients... CONCLUSION: Plerixafor and G-CSF were well tolerated and resulted in a significantly higher proportion of patients with non-Hodgkin's lymphoma achieving the optimal CD34+ cell target for transplantation in fewer apheresis days, compared with G-CSF alone.
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. [2009.06.04]
This phase 3, multicenter, randomized (1:1), double-blind, placebo-controlled study evaluated the safety and efficacy of plerixafor with granulocyte colony-stimulating factor (G-CSF) in mobilizing hematopoietic stem cells in patients with multiple myeloma... Plerixafor and G-CSF were well tolerated, and significantly more patients collected the optimal CD34(+) cell/kg target for transplantation earlier compared with G-CSF alone.
Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. [2011.08.20]
Plerixafor (Mozobil(R)) is a CXCR4 chemokine receptor antagonist that is indicated for use in combination with granulocyte colony-stimulating factor (G-CSF) to mobilize stem cells to the peripheral blood for collection and subsequent autologous stem-cell transplantation in patients who have non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM) [US] and in patients who have lymphoma or MM and are poor mobilizers (EU)...
Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. [2011.07]
The introduction of plerixafor has enabled successful collection of stem cells in the majority of patients with lymphoma or myeloma in whom previous attempts at mobilization have failed. However, a proportion of patients have been shown to be resistant to this mobilization regimen... Patients who are characterized by the above negative features could benefit potentially from further improvement in the mobilization strategy.
Clinical Trials Related to Mozobil (Plerixafor Subcutaneous)
Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major [Completed]
Thalassemia is considered the most common genetic disorder worldwide, occurring with high
frequency in Mediterranean areas, the Middle East, Southeast Asia, and the Pacific Islands.
Currently, the only cure for thalassemia is bone marrow transplantation from a related,
compatible donor. Gene transfer, achieved by transplantation of the patient's own blood
stem cells that have been genetically-modified with the corrected gene, could potentially
The first step in developing gene transfer for treatment of thalassemia is to develop a safe
and effective method to obtain blood stem cells from thalassemia patients. Eventually, high
numbers of genetically modified cells will need to be infused into the patient for clinical
gene transfer to be effective. The blood stem cells are obtained by giving a "mobilization"
agent to the patients. This causes the stem cells to leave the bone marrow and go into the
blood. The purpose of this study is to test the safety and effectiveness of the new
mobilization agent, Mozobil, in causing mobilization of blood stem cells for patients with
Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma [Recruiting]
Plerixafor in combination with bevacizumab is a drug combination that may stop cancer cells
from growing abnormally. Bevacizumab, also known as Avastin, is FDA approved for use in
patients with recurrent glioblastoma and has been studied extensively in other types of
solid tumors. Plerixafor, also known as Mozobil, is FDA approved for use in patients with
non-Hodgkin's lymphoma and multiple myeloma and has been used in treatment for other
cancers. Information from experiments in laboratories suggests that the combination of
plerixafor and bevacizumab may help prevent the growth of gliomas.
Part 1: The investigators are looking for the highest dose of plerixafor that can be given
safely with bevacizumab (with a 21 days on/7 days off regimen of plerixafor). The
investigators will also do blood tests to find out how the body uses and breaks down the
Part 2: The investigators are looking to see if plerixafor can get past the blood-brain
barrier and into brain tumors. The investigators will also do blood tests to find out how
the body uses and breaks down the drug combination.
Part 3: The investigators are looking for for more information re: safety and tolerability
of plerixafor in combination with bevacizumab (with a 28 days on/0 days off regimen of
plerixafor). The investigators will also do blood tests to find out how the body uses and
breaks down the drug combination.
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia [Completed]
This study is a phase I/II study to determine the safety and efficacy of AMD3100 when
combined with mitoxantrone, etoposide, and cytarabine in patients with relapsed or
We hypothesize that disrupting the interaction between AML blasts and the marrow
microenvironment with AMD3100 may enhance the cytotoxic effect of chemotherapy.
G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers [Completed]
This 12-day study will test whether the combination of G-CSF (granulocyte-colony stimulating
factor) and AMD3100 (Mozobil) is more efficient in mobilizing stem cells for collection than
the use of G-CSF alone. Traditionally, the growth factor G-CSF has been given to stem cell
donors to mobilize, or push, stem cells out of the bone marrow and into the blood
circulation for collection for transplantation. Although a sufficient quantity of cells
usually can be collected with G-CSF treatment, some donors do not respond well and may
require multiple apheresis procedures (see below) to collect enough cells. Studies indicate
that G-CSF used together with a drug called AMD3100 may be more effective in mobilizing stem
cells for collection than G-CSF alone. The Food and Drug Administration has approved G-CSF
for stem cell mobilization. AMD3100 is a new drug that also mobilizes stem cells in large
numbers within a few hours.
Normal healthy volunteers between 18 and 60 years of age may be eligible for this study.
AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts [Completed]
This study evaluates the safety, efficacy, and pharmacokinetics (PK) of plerixafor given in
addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood
stem cells (PBSCs) for autologous transplantation in patients who would benefit from an
autologous stem cell transplant but have failed previous collections or collection attempts
with a mobilization regimen of G-CSF alone, chemotherapy and G-CSF, or any other
conventional therapy including cytokines, chemotherapy and cytokines and bone marrow
The only change to standard of care of a mobilization regimen that includes G-CSF is the
addition of a dose of AMD3100 (plerixafor) on the evening prior to each day of apheresis.
Efficacy outcomes include quantification of CD34+ cells in the apheresis product and
assessment of successful polymorphonuclear leukocyte (PMN) and platelet (PLT) engraftment
after transplantation. PK outcomes include analysis of repeated doses of plerixafor.
Reports of Suspected Mozobil (Plerixafor Subcutaneous) Side Effects
Febrile Neutropenia (30),
Respiratory Failure (15),
Pleural Effusion (14),
Interstitial Lung Disease (10),
Therapeutic Response Decreased (10), more >>